BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9457834)

  • 1. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer.
    Sur RK; Donde B; Levin VC; Mannell A
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):447-53. PubMed ID: 9457834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study.
    Sur RK; Levin CV; Donde B; Sharma V; Miszczyk L; Nag S
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):127-33. PubMed ID: 12007950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer.
    Sur R; Donde B; Falkson C; Ahmed SN; Levin V; Nag S; Wong R; Jones G
    Brachytherapy; 2004; 3(4):191-5. PubMed ID: 15607150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palliation of dysphagia in advanced, metastatic or recurrent carcinoma oesophagus with high dose rate intraluminal brachytherapy--an eastern Indian experience of 35 cases.
    Ghosh S; Sau S; Mitra S; Manna A; Ghosh K
    J Indian Med Assoc; 2012 Jul; 110(7):449-52. PubMed ID: 23520668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliation of advanced/recurrent esophageal carcinoma with high-dose-rate brachytherapy.
    Sharma V; Mahantshetty U; Dinshaw KA; Deshpande R; Sharma S
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):310-5. PubMed ID: 11872275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of outcome of single-dose brachytherapy for the palliation of dysphagia from esophageal cancer.
    Homs MY; Steyerberg EW; Eijkenboom WM; Siersema PD;
    Brachytherapy; 2006; 5(1):41-8. PubMed ID: 16563996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraluminal high-dose-rate brachytherapy for palliation of dysphagia in cancer of the esophagus: initial experience at a single UK center.
    Bhatt L; Tirmazy S; Sothi S
    Dis Esophagus; 2013 Jan; 26(1):57-60. PubMed ID: 22404484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliative treatment by high-dose-rate intraluminal brachytherapy in patients with advanced esophageal cancer.
    Skowronek J; Piotrowski T; Zwierzchowski G
    Brachytherapy; 2004; 3(2):87-94. PubMed ID: 15374540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group.
    Okawa T; Dokiya T; Nishio M; Hishikawa Y; Morita K
    Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):623-8. PubMed ID: 10524414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
    Calais G; Dorval E; Louisot P; Bourlier P; Klein V; Chapet S; Reynaud-Bougnoux A; Huten N; De Calan L; Aget H; Le Floch O
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):769-75. PubMed ID: 9240645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: a randomised study.
    Spencer GM; Thorpe SM; Blackman GM; Solano J; Tobias JS; Lovat LB; Bown SG
    Gut; 2002 Feb; 50(2):224-7. PubMed ID: 11788564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliation of carcinoma of the oesophagus with brachytherapy and the Didcott dilator.
    Sur RK; Didcott CC; Levin CV; Kulhavy M; Donde B; Schafer M; Gavenescu J
    Ann R Coll Surg Engl; 1996 Mar; 78(2):124-8. PubMed ID: 8678445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring relief of dysphagia in locally advanced esophageal carcinoma patients submitted to high-dose-rate brachytherapy.
    Grazziotin Reisner R; Reisner ML; Ferreira MA; Rosa AA; Veras IM; Carneiro TM; Wolff B; Viégas CM; Mendonça de Araújo CM; Marchiori E
    Brachytherapy; 2015; 14(1):84-90. PubMed ID: 25447340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of intraluminal brachytherapy dose on complications in the treatment of esophageal cancer.
    Kumar MU; Swamy K; Supe SS; Anantha N
    Int J Radiat Oncol Biol Phys; 1993 Dec; 27(5):1069-72. PubMed ID: 8262829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined stent insertion and single high-dose brachytherapy in patients with advanced esophageal cancer--results of a prospective safety study.
    Bergquist H; Johnsson E; Nyman J; Rylander H; Hammerlid E; Friesland S; Ejnell H; Lundell L; Ruth M
    Dis Esophagus; 2012 Jul; 25(5):410-5. PubMed ID: 21899654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection.
    Steyerberg EW; Homs MY; Stokvis A; Essink-Bot ML; Siersema PD;
    Gastrointest Endosc; 2005 Sep; 62(3):333-40. PubMed ID: 16111947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of multidisciplinary treatment with high dose rate intraluminal brachytherapy on survival in patients with unresectable esophageal cancer.
    Iwasa M; Ohmori Y; Iwasa Y; Yamamoto A; Inoue A; Maeda H; Kume M; Ogoshi S; Nishioka A; Ogawa Y; Yoshida S
    Dig Surg; 1998; 15(3):227-35. PubMed ID: 9845590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer.
    Hirdes MM; van Hooft JE; Wijrdeman HK; Hulshof MC; Fockens P; Reerink O; van Oijen MG; van der Tweel I; Vleggaar FP; Siersema PD
    Gastrointest Endosc; 2012 Aug; 76(2):267-74. PubMed ID: 22695208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous hyperfractionated accelerated radiotherapy (CHART) in localized cancer of the esophagus.
    Powell ME; Hoskin PJ; Saunders MI; Foy CJ; Dische S
    Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):133-6. PubMed ID: 9212014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliation in esophageal cancer with a single session of intraluminal irradiation.
    Jager JJ; Pannebakker M; Rijken J; de Vos J; Vismans FJ
    Radiother Oncol; 1992 Oct; 25(2):134-6. PubMed ID: 1279749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.